Cerity Partners
PBYI icon

Cerity Partners’s Puma Biotechnology PBYI Stock Holding History

Cerity Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.3K Sell
10,512
-2,501
-19% -$18.3K ﹤0.01% 3235
2026
Q1 		$83.2K Buy
13,013
+941
+8% +$6.07K ﹤0.01% 3042
2025
Q4 		$71.8K Buy
12,072
+1,862
+18% +$9.89K ﹤0.01% 2783
2025
Q3 		$54.2K Sell
10,210
-318
-3% -$1.35K ﹤0.01% 2690
2025
Q2 		$36.1K Buy
+10,528
New +$33.6K ﹤0.01% 2572

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's PBYI Position: Q2 2026 in Review

Cerity Partners reduced its Puma Biotechnology (PBYI) stake by 19% in Q2 2026, selling an estimated $18.3K and leaving 10,512 shares worth $85.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3235.

Cerity Partners first reported a position in PBYI in Q2 2025 and has held it in 5 quarters since. 151 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Cerity Partners held 10,512 shares of Puma Biotechnology worth $85.3K as of Q2 2026.
  • Cerity Partners sold 2,501 Puma Biotechnology shares in Q2 2026, an estimated $18.3K.
  • Puma Biotechnology made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3235 holding.
  • Cerity Partners first reported a position in Puma Biotechnology in Q2 2025 and has held it in 5 quarters since.
  • 151 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.